Evidence map›Paper›PMID 35456436›Full record

ArticleGenes2022

Technological Advances:

Ratilal Akabari, Dahui Qin, Mohammad Hussaini

Open access · goldAbstract read
In one paragraph

Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ratilal AkabariDepartment of Pathology, Molecular Oncology and Genetics Diagnostics, SUNY Upstate Medical University, Syracuse, NY 13210, USA.
Dahui QinDepartment of Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA.
Mohammad HussainiDepartment of Pathology, Moffitt Cancer Center, Tampa, FL 33612, USA.ORCID 0000-0001-5192-0489
Moffitt Cancer Center · USSUNY Upstate Medical University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe detection of

methodsAmplicon-based TSM 54-Gene Panel (Illumina) was evaluated against hybridization-capture SOPHiA Genetics MSP, OGT SureSeq, and AMP chemistry-based VariantPlex (Archer) for wet-lab workflow and data-analysis pipelines. Standard kit directions and commercial analysis pipelines were followed. Seven

resultsAll three panels detected all 10

conclusionsThe results show that the NGS assays are now able to reliably detect

Indexed as

High-Throughput Nucleotide SequencingLeukemia, Myeloid, AcuteCCAAT-Enhancer-Binding Proteinsfms-Like Tyrosine Kinase 3HumansMutationTandem Repeat SequencesCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3AMLCEBPAFLT3Internal Tandem Duplication (ITD)next generation sequencing (NGS)

Identifiers

PMID35456436
PMCPMC9028339
OpenAlexW4224326733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.